EAN 2024: Treatment cessation and reinitiation can reduce benefits of Ajovy [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
analysis from the observational, prospective Phase IV Pan-European Real-Life (PEARL) study of Teva Pharmaceuticals' Ajovy for the management of migraine was presented. The results focused on the effects of treatment cessation and reinitiation. Ajovy is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) that was approved in Europe in 2019 as a preventive treatment for adults with episodic and chronic migraine. The aim of preventive therapy is to reduce the frequency, severity, or duration of attacks, with the anti-CGRP mAbs commonly used as third-line options following failure to respond to at least two oral preventive therapies. The PEARL study is an ongoing 24-month study evaluating Ajovy for migraine prevention in 1,140 adults across 11 European countries. Interim analysis from the PEARL study focused on 220 participants who had a documented treatment cessation, with 192 of those also having a documented treatment reinitiation. The data presented sh
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Global Herpes Treatment Market Size To Worth USD 1.87 Billion By 2033 | CAGR Of 4.28% [Yahoo! Finance]Yahoo! Finance
- Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024Business Wire
- FTC investigates Teva over contested product patents [Yahoo! Finance]Yahoo! Finance
- Real-World Evidence and Life Science Analytics 2 Day Conference (Boston, USA - October 17th-18th 2024) - Shaping the Future of Healthcare [Yahoo! Finance]Yahoo! Finance
- Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 5/8/24 - Miss
TEVA
Sec Filings
- 6/25/24 - Form 8-K
- 6/21/24 - Form 4
- 6/18/24 - Form 144
- TEVA's page on the SEC website